CBL anticorps (AA 556-906)

N° du produit ABIN3043746

Cet anticorps anti-CBL est un anticorps Lapin Polyclonal détectant CBL dans WB, IHC, IF, ICC et FACS. Adapté pour Humain, Souris et Rat.

Aperçu rapide pour CBL anticorps (AA 556-906) (ABIN3043746)

Antigène: CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CBL est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunocytochemistry (ICC), Flow Cytometry (FACS)

Détail du produit anti-CBL anticorps

Épitope: AA 556-906

Fonction: Anti-CBL Antibody Picoband®

Réactivité croisée (Details): No cross-reactivity with other proteins

Attributs du produit: Anti-CBL Antibody Picoband® (ABIN3043746). Tested in Flow Cytometry, IF, IHC, ICC, WB applications. This antibody reacts with Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Purification: Immunogen affinity purified.

Immunogène: E.coli-derived human CBL recombinant protein (Position: A556-T906). Human CBL shares 84% amino acid (aa) sequence identity with mouse CBL.

Isotype: IgG

Information d'application

Indications d'application: Western blot, 0.1-0.5 μg/mL, Human, Mouse, Rat
Immunohistochemistry (Paraffin-embedded Section), 0.5-1 μg/mL, Human, Mouse, Rat
Immunocytochemistry/Immunofluorescence, 2 μg/mL, Human
Flow Cytometry (Fixed), 1-3 μg/1x10⁶ cells, Human1. Joazeiro, C. A. P., Wing, S. S., Huang, H., Leverson, J. D., Hunter, T., Liu, Y.-C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286: 309-312, 1999. 2. Martinelli, S., De Luca, A., Stellacci, E., Rossi, C., Checquolo, S., Lepri, F., Caputo, V., Silvano, M., Buscherini, F., Consoli, F., Ferrara, G., Digilio, M. C., and 14 others.Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am. J. Hum. Genet. 87: 250-257, 2010. 3. Wei, S., Rocchi, M., Archidiacono, N., Sacchi, N., Romeo, G., Gatti, R. A. Physical mapping of the human chromosome 11q23 region containing the ataxia-telangiectasia locus. Cancer Genet. Cytogenet. 46: 1-8, 1990.

Commentaires:

Antibody can be supported by chemiluminescence kit ABIN921124 in WB.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Concentration: 500 μg/mL

Buffer: Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

Détails sur CBL

Antigène: CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))

Autre désignation: CBL

Sujet:

Synonyms: E3 ubiquitin-protein ligase CBL,6.3.2.-,Casitas B-lineage lymphoma proto-oncogene,Proto-oncogene c-Cbl,RING finger protein 55,Signal transduction protein CBL,CBL,CBL2, RNF55,

Tissue Specificity: Ubiquitous.

Background: CBL (Cbl proto-oncogene) is also known as C-CBL, RNF55, CBL2 and E3 ubiquitin protein ligase. CBL is mapped to chromosome 11q23.3-qter by molecular characterization of the breakpoints in 2 somatic cell hybrids. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder.

Sequence Similarities: Contains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.

Poids moléculaire: 120 kDa

ID gène: 867

UniProt: P22681

Pathways: TCR Signaling, Interferon-gamma Pathway, EGFR Signaling Pathway, EGFR Downregulation, VEGFR1 Specific Signals